HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: A case report

The Lancet HIV

Volumn 3, Issue 1, 2016, Pages e49-e54

  Frange, Pierre ^a,b   Faye, Albert ^b,c   Avettand Fenoël, Véronique ^a,b   Bellaton, Erianna ^c   Descamps, Diane ^d,f   Angin, Mathieu ^a   David, Annie ^a   Caillat Zucman, Sophie ^c,e   Peytavin, Gilles ^d,f   Dollfus, Catherine ^h   Le Chenadec, Jerome ⁱ   Warszawski, Josiane ^i,j   Rouzioux, Christine ^g,h   Sáez Cirión, Asier ^g  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL ROBERT DEBRÉ   (France)

^d UNIVERSITÉ PARIS DIDEROT   (France)

^e CENTRE DE RECHERCHE SUR L INFLAMMATION   (France)

^f BICHAT HOSPITAL   (France)

^g INSTITUT PASTEUR   (France)

^h ARMAND TROUSSEAU HOSPITAL   (France)

ⁱ CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^j BICÊTRE HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; ANTIRETROVIRUS AGENT; CD4 ANTIBODY; DIDANOSINE; GAMMA INTERFERON; GLYCOPROTEIN GP 110; GLYCOPROTEIN GP 160; GLYCOPROTEIN GP 41; INTERLEUKIN 2; LAMIVUDINE; NELFINAVIR; PHYTOHEMAGGLUTININ; PROTEIN P40; PROTEIN P55; PROTEIN P68; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; ANEMIA; ARTICLE; CASE REPORT; CHILD; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV RAPID TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; INFANT; INTRAPARTUM CARE; LONG TERM CARE; MONOTHERAPY; NEUTROPENIA; NEWBORN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROPHYLAXIS; REMISSION; VAGINAL DELIVERY; VIROLOGY; VIRUS LOAD; WESTERN BLOTTING; COHORT ANALYSIS; DRUG EFFECTS; FOLLOW UP; FRANCE; HIV INFECTIONS; INFANT, NEWBORN, DISEASES; PHYSIOLOGY; SECONDARY PREVENTION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ADOLESCENT; ANTI-HIV AGENTS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; FRANCE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; SECONDARY PREVENTION; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 84952896973     PISSN: None     EISSN: 23523018     Source Type: Journal    
DOI: 10.1016/S2352-3018(15)00232-5     Document Type: Article

References (25)

1. Sáez-Cirión A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013, 9:e1003211.
2. Persaud D, Gay G, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013, 369:1828-1835.
3. Luzuriaga K, Gay H, Ziemniak C, et al. Viremic relapse after HIV-1 remission in a perinatally infected child. N Engl J Med 2015, 372:786-788.
4. Dollfus C, Lechenadec J, Faye A, et al. Long-term outcomes of adolescents perinatally infected with HIV-1 and followed since birth in the French Pediatric Cohort EPF-ANRS C010. Clin Infect Dis 2010, 51:214-224.
5. Rouet F, Chaix ML, Nerrienet E, et al. Impact of HIV-1 genetic diversity on plasma HIV-1 RNA Quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test. J Acquir Immune Defic Syndr 2007, 45:380-388.
6. Avettand-Fènoël V, Chaix ML, Blanche S, et al. LTR real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01). J Med Virol 2009, 81:217-223.
7. Jung BH, Rezk NL, Bridges AS, Corbett AH, Kashuba AD Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 2007, 21:1095-1104.
8. Sáez-Cirión A, Lacabaratz C, Lambotte O, et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci USA 2007, 104:6776-6781.
9. Sáez-Cirión A, Shin SY, Versmisse P, Barré-Sinoussi F, Pancino G Ex vivo T cell-based HIV supression assay to evaluate HIV-specific CD8+ T cell responses. Nat Proc 2010, 5:1033-1034.
10. Scott-Algara D, Rouzioux C, Blanche S, et al. In untreated HIV-1-infected children, PBMC-associated HIV DNA levels and cell-free HIV RNA levels are correlated to distinct T-lymphocyte populations. J AIDS 2010, 53:553-563.
11. Cohen Stuart JW, Hazebergh MD, Hamann D, et al. The dominant source of CD4+ and CD8+ T-cell activation in HIV infection is antigenic stimulation. J Acquir Immune Defic Syndr 2000, 25:203-211.
12. Burgard M, Blanche S, Jasseron C, et al. Performance of HIV-1 DNA or HIV-1 RNA tests for early diagnosis of perinatal HIV-1 infection during anti-retroviral prophylaxis. J Pediatr 2012, 160:60-66.
13. Delaugerre C, Warszawski J, Chaix ML, et al. Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children. J Med Virol 2007, 79:1261-1269.
14. Frange P, Assoumou L, Descamps D, et al. HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-12: impact on susceptibility to first-line strategies. J Antimicrob Chemother 2015, 70:2084-2089.
15. Sáez-Cirión A, Pancino G HIV controllers: a genetically determined or inducible phenotype?. Immunol Rev 2013, 254:281-294.
16. Carrington M, Nelson GW, Martin MP, et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 1999, 283:1748-1752.
17. Tang J, Costello C, Keet IP, et al. HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 1999, 15:317-324.
18. Scott-Algara D, Didier C, Arnold V, et al. Post-treatment controllers have particular NK cells with high anti-HIV capacity: VISCONTI Study. Conference on Retroviruses and Opportunistic Infections (CROI); Seattle, WA, USA; Feb 23-26, 2015. Abstract 52.
19. Shearer WT, Rosenblatt HM, Gelman RS, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol 2003, 112:973-980.
20. Schatorjé EJ, Gemen EF, Driessen GJ, Leuvenink J, van Hout RW, de Vries E Paediatric reference values for the peripheral T cell compartment. Scand J Immunol 2012, 75:436-444.
21. Luzuriaga K, Tabak B, Garber M, et al. HIV type 1 (HIV-1) proviral reservoirs decay continuously under sustained virologic control in HIV-1-infected children who received early treatment. J Infect Dis 2014, 210:1529-1538.
22. Giacomet V, Trabattoni D, Zanchetta N, et al. No cure of HIV infection in a child despite early treatment and apparent viral clearance. Lancet 2014, 384:1320.
23. Martínez-Bonet M, Puertas MC, Fortuny C, et al. Establishment and replenishment of the viral reservoir in perinatally HIV-1-infected children initiating very early antiretroviral therapy. Clin Infect Dis 2015, 61:1169-1178.
24. Butler KM, Gavin P, Coughlan S, et al. Rapid viral rebound after 4 years of suppressive therapy in a seronegative HIV-1 infected infant treated from birth. Pediatr Infect Dis J 2015, 34:e48-e51.
25. Castro H, Judd A, Gibb DM, et al. Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet 2011, 377:1580-1587. Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE).